Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleNew research indicates that while Wegovy pills are effective for weight loss, they may not offer the same heart health advantages as their injectable counterparts. A comprehensive review published in the British Medical Journal analysed 19 obesity treatments, finding that most, including popular options like Wegovy and Mounjaro, do not significantly improve overall quality of life. The study revealed that greater weight loss achieved through these medications was often associated with an increased likelihood of side effects, such as stomach issues and the loss of lean muscle mass. Wegovy injections were identified as the only drug linked to a reduced risk of death from any cause, heart attack, and heart failure, with Mounjaro also showing a reduction in heart failure risk. Researchers noted that most clinical trials had relatively short follow-up periods, limiting definitive conclusions on long-term safety, quality of life, and effects on heart and kidney health, emphasising the need for individualised treatment decisions. In fullStudy finds most weight loss drugs including Wegovy and Mounjaro ‘do not improve quality of life’More bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Weight loss drugs found to ‘not improve quality of life’
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleNew research indicates that while Wegovy pills are effective for weight loss, they may not offer the same heart health advantages as their injectable counterparts. A comprehensive review published in the British Medical Journal analysed 19 obesity treatments, finding that most, including popular options like Wegovy and Mounjaro, do not significantly improve overall quality of life. The study revealed that greater weight loss achieved through these medications was often associated with an increased likelihood of side effects, such as stomach issues and the loss of lean muscle mass. Wegovy injections were identified as the only drug linked to a reduced risk of death from any cause, heart attack, and heart failure, with Mounjaro also showing a reduction in heart failure risk. Researchers noted that most clinical trials had relatively short follow-up periods, limiting definitive conclusions on long-term safety, quality of life, and effects on heart and kidney health, emphasising the need for individualised treatment decisions. In fullStudy finds most weight loss drugs including Wegovy and Mounjaro ‘do not improve quality of life’More bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
